Matt Fates
General Partner @ Ascent Venture Partners
Boston, United States
Matt Fates is a seed investor at Ascent Venture Partners in Boston focused on Software and Biotechnology. Matt Fates is the Partner - AI VC at Innospark Ventures.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 59%
Last updated:
For AI agents: llms.txt
Industries Matt Fates invests in
Stages Matt Fates invests in
Countries Matt Fates invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 6 (27%)
- Biotechnology 5 (23%)
- Machine Learning 4 (18%)
- Enterprise Software 4 (18%)
- Artificial Intelligence 4 (18%)
Stage
- Seed 6 (27%)
- Series A 5 (23%)
- Series B 5 (23%)
- Series C 3 (14%)
- Funding Round 1 (5%)
Country
- United States 9 (41%)
- Canada 4 (18%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $9.3M / Series A / Mar 03, 2026 | ||
| PhaseShift Technologies is addressing the critical need for new materials that can overcome limitations in performance, efficiency, cost, availability, and sustainability. Traditional material development relies heavily on trial-and-error, requiring costly and time-consuming physical experiments. This approach can extend projects over 10-20 yearsand cost millions of dollars, with no guarantee of success.PhaseShift's Rapid Alloy Design (RAD)™ technology revolutionizes this process by using AI to create optimized alloys tailored to specific use cases. Paired with Multi-Scale Simulations to accurately predict material performance, RAD™ minimizes the time and effort spent on unsuccessful trials. This leads to faster, more efficient development cycles and a significant reduction in resources required to meet design goals.Through the RAD™ platform, PhaseShift designs a portfolio of innovative alloys, which are commercialized via strategic partnerships with manufacturers. | $3M / Seed / Oct 21, 2024 | ||
| Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $4.6M / Seed / Oct 15, 2024 | ||
| BioIntelligence Technology develops intelligent monitoring instruments to accelerate bioprocess development for biotechnology industries. They provide solutions for microorganisms or cells to biosynthesize a molecule or a group of molecules. | $3.7M / Seed / Apr 23, 2024 | ||
| Via Scientific to help scientists and bioinformaticians generate novel science that improves the world. It was founded in 2022. | $5M / Seed / Jan 09, 2024 | ||
| Persist assist pharmaceutical companies in developing long-acting formulations 50% faster. Because the formulation development process is manual and relies on scientific intuition, it takes a pharmaceutical company 5-10 years to develop a long acting formulation for a drug. This effort is divided into five years of pre-clinical development and fiveyears of clinical testing. Their goal is to use machine learning and automation to reduce the time required for pre-clinical formulation development to three months, making the formulation development process 50% faster. | $4M / Seed / Apr 12, 2023 | ||
| Antiverse is a new type of antibody discovery company accelerating drug development. Its platform exists at the intersection of structural biology, machine learning, and medicine to enable breakthroughs to happen more quickly and cost-effectively. It is dedicated to engineering the future of drug development to change the course of people'slives. | $3M / Seed / Mar 01, 2023 | ||
| Connectbase utilizes location-based insights and automation to buy and sell connectivity. Its platform drives growth for the clients by increasing visibility to the market, managing location, and driving engagement as the system of record where connectivity providers connect and pass by in the commercial market. | $21M / Series C / Sep 22, 2022 | ||
| Dyania Health develops a research platform for pharma companies and hospital systems. Its health platform identifies match patients, then the pharma and CROs send a referral request to the patient’s physician or clinic, and if the patient is the right fit for the clinical trials they can join the trials.The company was founded in 2019 and isbased in Los Angeles, California. | $5.3M / Seed / Sep 08, 2022 | ||
| ODAIA has innovated the first AI-powered Customer Data Platform (CDP) that pioneered the combination of process mining, customer journey mapping and AI to deliver goal-driven commercial insights and process automation as a SaaS for the Life Sciences industry. | $13.8M / Series A / Feb 10, 2022 | ||
| See all 22 investments → | |||
Co-Investors
About Ascent Venture Partners
Ascent is a venture capital firm that invests in early stage, emerging technology companies. At Ascent, they don’t jump on the latest trends in general technology. Instead, they remain dedicated to investing in a singular space with enormous market potential -- enterprise IT innovation. Their singular focus on enterprise IT, combined with their 28 years of experience and over 100 early stage investments, has yielded powerful results that speak to their deep knowledge, expertise, commitments and networks. Today, enterprise IT is in the midst of tremendous disruption. Between the shift to the cloud, mobility, consumerization of IT, data analytics and entirely new security architectures, both major challenges and tremendous opportunities abound. Over the next decade, the enterprise IT market will be transformed by these disruptive trends, providing lucrative opportunities for innovative early stage companies to emerge, develop new markets, and become the dominant IT companies of the future. They have a firm-wide commitment to backing companies that have courageous ideas about how technology can transform business and create market-leading companies along the way. Their partners, funds and extensive network are dedicated entirely to supporting companies in the enterprise IT arena, and helping them to be the best they can be. Ascent invests in early stage companies in the east coast with initial investment ranging from $2 million to $5 million.
Ascent Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Baiyin Murphy
Principal
|
|||
Luke Burns
General Partner
|
|||
Baiyin Murphy
Principal
|
|||
Brian J. Girvan
General Partner
|
|||
Christopher W. Dick
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Matt Fates invest in?
Matt Fates invests primarily in Software, Biotechnology and Machine Learning startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Matt Fates?
Public channels for Matt Fates include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Matt Fates last invest?
The most recent investment recorded for Matt Fates closed in Mar 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
